Aegis reaffirmed their buy rating on shares of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) in a report issued on Thursday morning. Aegis currently has a $63.00 price objective on the stock.

Other equities research analysts have also recently issued research reports about the company. Needham & Company LLC reissued a buy rating and issued a $52.00 price target (up previously from $45.00) on shares of Aerie Pharmaceuticals in a research note on Thursday, September 15th. Cantor Fitzgerald reissued a buy rating and issued a $50.00 price target on shares of Aerie Pharmaceuticals in a research note on Saturday, October 8th. Brean Capital set a $48.00 price target on Aerie Pharmaceuticals and gave the company a buy rating in a research note on Thursday, September 29th. Zacks Investment Research cut Aerie Pharmaceuticals from a buy rating to a hold rating in a research note on Thursday, November 3rd. Finally, RBC Capital Markets reissued an outperform rating and issued a $55.00 price target on shares of Aerie Pharmaceuticals in a research note on Friday, October 21st. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Aerie Pharmaceuticals presently has an average rating of Buy and an average price target of $51.91.

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Shares of Aerie Pharmaceuticals (NASDAQ:AERI) opened at 39.75 on Thursday. The stock’s 50 day moving average is $36.86 and its 200-day moving average is $23.58. Aerie Pharmaceuticals has a 52-week low of $10.82 and a 52-week high of $41.72. The firm’s market cap is $1.33 billion.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its earnings results on Wednesday, November 2nd. The company reported ($0.67) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.67). Equities analysts anticipate that Aerie Pharmaceuticals will post ($2.84) earnings per share for the current fiscal year.

In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Fund Ii, L.P. sold 50,000 shares of the company’s stock in a transaction on Thursday, October 6th. The stock was sold at an average price of $40.34, for a total value of $2,017,000.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 8.77% of the company’s stock.

A number of hedge funds have recently made changes to their positions in AERI. Jennison Associates LLC boosted its stake in shares of Aerie Pharmaceuticals by 0.6% in the second quarter. Jennison Associates LLC now owns 3,711,695 shares of the company’s stock valued at $65,326,000 after buying an additional 21,505 shares during the last quarter. Deerfield Management Co. boosted its stake in shares of Aerie Pharmaceuticals by 225.9% in the first quarter. Deerfield Management Co. now owns 2,632,482 shares of the company’s stock valued at $32,011,000 after buying an additional 1,824,607 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in shares of Aerie Pharmaceuticals by 3.7% in the second quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company’s stock valued at $36,960,000 after buying an additional 75,000 shares during the last quarter. BlackRock Fund Advisors boosted its stake in shares of Aerie Pharmaceuticals by 7.3% in the third quarter. BlackRock Fund Advisors now owns 1,042,480 shares of the company’s stock valued at $39,343,000 after buying an additional 70,584 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Aerie Pharmaceuticals by 11.1% in the second quarter. Vanguard Group Inc. now owns 1,006,552 shares of the company’s stock valued at $17,716,000 after buying an additional 100,645 shares during the last quarter. Hedge funds and other institutional investors own 84.35% of the company’s stock.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

5 Day Chart for NASDAQ:AERI

Receive News & Stock Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.